← Back to Search

PI3K Inhibitor

Inavolisib for Solid Cancers and Breast Cancer

Phase 1
Waitlist Available
Research Sponsored by Genentech, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Female participants with locally advanced or metastatic PIK3CA-mutant HER2+ breast cancer (Stage II Arm G)
All participants must provide tumor tissue from the primary or metastatic tumor site obtained from a prior or new biopsy or surgical procedure for detection of PIK3CA mutation by central laboratory test (Stages I and II)
Must not have
Known and untreated, or active central nervous system metastases
Congenital long QT syndrome, prolonged QT interval, or family history of sudden unexplained death or long QT syndrome
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial tests inavolisib, an oral drug, in patients with advanced or metastatic PIK3CA-mutant solid tumors, including breast cancer. The drug works by blocking a protein that helps cancer cells grow.

Who is the study for?
This trial is for adults with advanced or metastatic solid tumors, including breast cancer, that have a specific mutation (PIK3CA). Participants must be in good physical condition (ECOG 0 or 1) and expected to live at least 12 weeks. Women with hormone receptor-positive/HER2-negative or HER2-positive breast cancer are eligible. Key exclusions include recent other cancers, significant heart conditions, uncontrolled illnesses, prior treatments with certain drugs, and inability to swallow pills.
What is being tested?
The study tests the drug Inavolisib alone or combined with standard therapies for advanced breast cancer. It's an open-label Phase I trial with two stages: dose-escalation to find safe amounts of Inavolisib and expansion to see how well it works across seven different treatment combinations involving drugs like Palbociclib, Letrozole, Fulvestrant, Metformin, Trastuzumab and Pertuzumab.
What are the potential side effects?
Possible side effects may include digestive issues; changes in blood counts affecting liver and kidney function; fatigue; reactions related to the heart such as irregular heartbeat; potential interactions leading to increased risk of infection due to immune system effects; skin reactions; and symptoms from nervous system involvement.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am a woman with advanced breast cancer that is HER2 positive and has a PIK3CA mutation.
Select...
I can provide a tissue sample from my cancer for testing.
Select...
My cancer is advanced, cannot be cured, and has a PIK3CA mutation.
Select...
I am fully active or restricted in physically strenuous activity but can do light work.
Select...
My heart pumps blood well (ejection fraction is 50% or more).
Select...
I am a woman with advanced breast cancer that is hormone receptor positive and HER2 negative.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have untreated brain metastases.
Select...
I have a long QT syndrome or a family history of sudden death related to it.
Select...
My breast cancer is of a rare type called metaplastic.
Select...
I have had cancer spread to the lining of my brain and spinal cord.
Select...
I do not have any serious infections needing IV antibiotics.
Select...
I have received more than 360 mg/m2 of doxorubicin.
Select...
I do not have uncontrolled high blood pressure or unstable chest pain.
Select...
I have or had heart rhythm problems or heart failure needing medication.
Select...
I have uncontrolled fluid buildup in my chest or abdomen.
Select...
I take medication to manage my Type 1 or Type 2 diabetes.
Select...
I do not have conditions that affect how my body absorbs food.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

9Treatment groups
Experimental Treatment
Group I: Stage II Arm G: Inavolisib + Trastuzumab + PertuzumabExperimental Treatment3 Interventions
Participants will receive inavolisib in combination with trastuzumab and pertuzumab (Days 1-21). Dose of inavolisib will be determined from the results of Stage I Arm A. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
Group II: Stage II Arm F: Inavolisib + Palbociclib + Fulvestrant + MetforminExperimental Treatment4 Interventions
Participants will receive inavolisib (Days 1-28) in combination with palbociclib (Days 1-21), fulvestrant (Days 1 and 15 of Cycle 1; Day 1 for subsequent cycles) and metformin (Days 1-28)(Cycle = 28 days). Dose of inavolisib will be determined from the results of Stage I Arm B. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
Group III: Stage II Arm E: Inavolisib + Palbociclib + FulvestrantExperimental Treatment3 Interventions
Participants will receive inavolisib (Days 1-28) in combination with palbociclib (Days 1-21) and fulvestrant (Days 1 and 15 of Cycle 1; Day 1 for subsequent cycles)(Cycle = 28 days). Dose of inavolisib will be determined from the results of Stage I Arm B. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
Group IV: Stage II Arm D: Inavolisib + FulvestrantExperimental Treatment2 Interventions
Participants will receive inavolisib on Days 1-28 in combination with fulvestrant on Day 1 and 15 of Cycle 1 and then on Day 1 from Cycle 2 (cycle length: 28 days). Dose of inavolisib will be decided based on the results of Stage I Arm C. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
Group V: Stage II Arm C: Inavolisib + LetrozoleExperimental Treatment2 Interventions
Participants will receive inavolisib in combination with letrozole on Days 1-28 of each 28-day cycle. Dose of inavolisib will be decided based on the results of Stage I Arm C. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
Group VI: Stage II Arm B: Inavolisib + Palbociclib + LetrozoleExperimental Treatment3 Interventions
Participants will receive inavolisib on Days 1-28 in combination with palbociclib on Days 1-21 and letrozole on Days 1-28 of each 28-day cycle. Dose of inavolisib will be decided based on the results of Stage I Arm B. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
Group VII: Stage I Arm C: Inavolisib + LetrozoleExperimental Treatment2 Interventions
Participants will receive inavolisib in escalating dose levels along with letrozole on Days 1-28 of each 28-day cycle. The starting dose of inavolisib will not exceed the starting dose in Stage I Arm A. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
Group VIII: Stage I Arm B: Inavolisib + Palbociclib + LetrozoleExperimental Treatment3 Interventions
Participants will receive inavolisib in escalating dose levels (starting dose 3 mg) on Days 1-28, palbociclib on Days 1-21, and letrozole on Days 1-28 of each 28-day cycle. Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
Group IX: Stage I Arm A: Inavolisib Single AgentExperimental Treatment1 Intervention
Participants will receive inavolisib in escalating dose levels with starting dose of 6 milligrams (mg). Participants will receive single dose of inavolisib on Day 1 of Cycle 1 followed by once daily from Day 8 of Cycle 1. (Cycle length: 35 days for Cycle 1 and 28 days for all other cycles). Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and unequivocal disease progression.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Letrozole
2002
Completed Phase 4
~3590
Fulvestrant
2011
Completed Phase 3
~3890
Metformin
2006
Completed Phase 4
~2430
Inavolisib
2021
Completed Phase 2
~260
Pertuzumab
2014
Completed Phase 3
~7500
Palbociclib
2017
Completed Phase 3
~3880
Trastuzumab
2014
Completed Phase 4
~5190

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for breast cancer, such as PIK3CA inhibitors, HER2 inhibitors, and CDK4/6 inhibitors, work by targeting specific molecular pathways that are altered in cancer cells. PIK3CA inhibitors block the PI3K/AKT/mTOR pathway, reducing tumor growth and proliferation. HER2 inhibitors target the HER2 protein, which is overexpressed in some breast cancers, while CDK4/6 inhibitors interfere with cell cycle progression. These targeted therapies are important for breast cancer patients as they provide more personalized and effective treatment options with potentially fewer side effects compared to traditional chemotherapy.
Promising novel therapies for the treatment of endometrial cancer.New drugs for breast cancer.Highlights from the 42nd annual meeting of the American Society of Clinical Oncology Atlanta, GA, USA, 2-6 June 2006.

Find a Location

Who is running the clinical trial?

Genentech, Inc.Lead Sponsor
1,554 Previous Clinical Trials
568,698 Total Patients Enrolled
96 Trials studying Breast Cancer
22,962 Patients Enrolled for Breast Cancer
Clinical TrialsStudy DirectorHoffmann-La Roche
2,217 Previous Clinical Trials
894,599 Total Patients Enrolled
136 Trials studying Breast Cancer
71,048 Patients Enrolled for Breast Cancer

Media Library

Inavolisib (PI3K Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT03006172 — Phase 1
Breast Cancer Research Study Groups: Stage I Arm A: Inavolisib Single Agent, Stage II Arm C: Inavolisib + Letrozole, Stage II Arm D: Inavolisib + Fulvestrant, Stage II Arm E: Inavolisib + Palbociclib + Fulvestrant, Stage II Arm F: Inavolisib + Palbociclib + Fulvestrant + Metformin, Stage II Arm G: Inavolisib + Trastuzumab + Pertuzumab, Stage I Arm B: Inavolisib + Palbociclib + Letrozole, Stage I Arm C: Inavolisib + Letrozole, Stage II Arm B: Inavolisib + Palbociclib + Letrozole
Breast Cancer Clinical Trial 2023: Inavolisib Highlights & Side Effects. Trial Name: NCT03006172 — Phase 1
Inavolisib (PI3K Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03006172 — Phase 1
~3 spots leftby Nov 2024